Leerink Swann reissued their outperform rating on shares of Epizyme, Inc. (NASDAQ:EPZM) in a research note released on Thursday morning. Leerink Swann currently has a $22.00 price objective on the biopharmaceutical company’s stock, down from their prior price objective of $28.00.
EPZM has been the topic of several other reports. Jefferies Group LLC began coverage on Epizyme in a research note on Wednesday, September 20th. They set a buy rating and a $23.00 target price on the stock. Cann restated a buy rating and set a $26.00 target price on shares of Epizyme in a research note on Tuesday, September 19th. Oppenheimer Holdings, Inc. restated a buy rating and set a $26.00 target price on shares of Epizyme in a research note on Tuesday, September 19th. Zacks Investment Research upgraded Epizyme from a hold rating to a buy rating and set a $20.00 target price on the stock in a research note on Monday, October 16th. Finally, Royal Bank Of Canada restated a buy rating and set a $20.00 target price on shares of Epizyme in a research note on Friday, September 15th. Three research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The stock has an average rating of Buy and a consensus target price of $22.67.
Shares of Epizyme (NASDAQ EPZM) traded up $0.15 during trading hours on Thursday, hitting $14.35. The stock had a trading volume of 188,548 shares, compared to its average volume of 587,390. Epizyme has a twelve month low of $8.90 and a twelve month high of $20.45.
Epizyme (NASDAQ:EPZM) last announced its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.65) by $0.02. sell-side analysts anticipate that Epizyme will post -2.25 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Epizyme, Inc. (EPZM) Receives “Outperform” Rating from Leerink Swann” was originally published by Community Financial News and is owned by of Community Financial News. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.com-unik.info/2017/11/06/epizyme-inc-epzm-receives-outperform-rating-from-leerink-swann.html.
In other news, Director David M. Mott purchased 200,000 shares of the company’s stock in a transaction on Monday, September 18th. The shares were acquired at an average price of $15.25 per share, for a total transaction of $3,050,000.00. Following the purchase, the director now owns 6,000 shares in the company, valued at $91,500. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Peter Tai-Ching Ho sold 15,000 shares of the business’s stock in a transaction dated Thursday, August 24th. The shares were sold at an average price of $15.68, for a total value of $235,200.00. Following the sale, the insider now owns 22,228 shares in the company, valued at approximately $348,535.04. The disclosure for this sale can be found here. In the last quarter, insiders have sold 45,000 shares of company stock worth $733,950. Company insiders own 25.20% of the company’s stock.
Institutional investors have recently bought and sold shares of the business. Legal & General Group Plc grew its stake in Epizyme by 8.9% during the 1st quarter. Legal & General Group Plc now owns 9,684 shares of the biopharmaceutical company’s stock valued at $165,000 after purchasing an additional 795 shares during the last quarter. UBS Asset Management Americas Inc. purchased a new stake in Epizyme during the 1st quarter valued at about $175,000. Fox Run Management L.L.C. purchased a new stake in Epizyme during the 3rd quarter valued at about $223,000. BB&T Securities LLC purchased a new stake in Epizyme during the 2nd quarter valued at about $181,000. Finally, Trexquant Investment LP purchased a new stake in Epizyme during the 2nd quarter valued at about $184,000. Institutional investors and hedge funds own 72.20% of the company’s stock.
Epizyme Company Profile
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
What are top analysts saying about Epizyme Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Epizyme Inc. and related companies.